Risk of Serious Bacterial and Non‐Bacterial Infections in People With MASLD DOI Creative Commons
Giovanni Targher, Herbert Tilg, Luca Valenti

et al.

Liver International, Journal Year: 2025, Volume and Issue: 45(4)

Published: March 12, 2025

ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has become the most common chronic globally. MASLD is a multisystem where metabolic dysfunction plays key role in development of and its relevant liver‐related morbidities extrahepatic complications, such as cardiovascular disease, kidney certain types cancers. Among least examined MASLD‐related an ever‐increasing number observational studies have reported positive association between risk serious bacterial infections (SBI) requiring hospital admission. This remained significant those statistical analysis was adjusted for age, sex, ethnicity, obesity, type 2 diabetes other comorbidities. Notably, incidence rates SBI were further increased with more advanced MASLD, especially patients cirrhosis, also observed some acute viral infections, including SARS‐CoV‐2 infection, leading to severe COVID‐19. In this narrative review article, we provide overview literature on (a) recent epidemiological data linking non‐bacterial admission, (b) putative underlying mechanisms through which may increase susceptibility both directly immune associated cirrhosis portal hypertension, (c) practical clinical implications growing global population MASLD.

Language: Английский

Alcohol-associated liver disease DOI Creative Commons
Bryan Mackowiak, Yaojie Fu, Luca Maccioni

et al.

Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: 134(3)

Published: Feb. 1, 2024

Alcohol-associated liver disease (ALD) is a major cause of chronic worldwide, and comprises spectrum several different disorders, including simple steatosis, steatohepatitis, cirrhosis, superimposed hepatocellular carcinoma. Although tremendous progress has been made in the field ALD over last 20 years, pathogenesis remains obscure, there are currently no FDA-approved drugs for treatment ALD. In this Review, we discuss new insights into therapeutic targets ALD, utilizing study multiomics other cutting-edge approaches. The potential translation these studies clinical practice therapy deliberated. We also preclinical models interplay metabolic dysfunction, alcohol-associated cancer, heterogeneity some translational research prospects

Language: Английский

Citations

112
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study DOI
Mads Israelsen, Nikolaj Torp, Stine Johansen

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2024, Volume and Issue: 9(3), P. 218 - 228

Published: Jan. 11, 2024

Language: Английский

Citations

68
Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes DOI Creative Commons
Luis Antonio Díaz, Eduardo Fuentes‐López, Francisco Idalsoaga

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 80(3), P. 409 - 418

Published: Nov. 21, 2023

The long-term impact of alcohol-related public health policies (PHPs) on disease burden is unclear. We aimed to assess the association between PHPs and consequences.

Language: Английский

Citations

45
From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research DOI
Cynthia L. Hsu, Rohit Loomba

Nature Metabolism, Journal Year: 2024, Volume and Issue: 6(4), P. 600 - 602

Published: Feb. 21, 2024

Language: Английский

Citations

38
Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population DOI
Carolin V. Schneider, Kai Markus Schneider,

A. Raptis

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 59(10), P. 1271 - 1281

Published: March 19, 2024

The prevalence of at-risk metabolic dysfunction-associated steatohepatitis (at-risk MASH) has not been systematically assessed.

Language: Английский

Citations

22
Metabolic Dysfunction and Alcohol-related Liver Disease (MetALD): Position statement by an expert panel on alcohol-related liver disease DOI
Juan Pablo Arab, Luis Antonio Díaz, Jürgen Rehm

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 1, 2024

Language: Английский

Citations

22
Global Epidemiology of Alcohol-Related Liver Disease, Liver Cancer, and Alcohol Use Disorder, 2000–2021 DOI Creative Commons
Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan

et al.

Clinical and Molecular Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 9, 2025

Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver (ALD). We aim to assess the global AUD, ALD, alcohol-attributable primary cancer between 2000-2021. registered regional trends using data from Global Burden Disease 2021 Study, largest most up-to-date epidemiology database. estimated annual percent change (APC) its 95% confidence interval (CI) changes in age-standardized rates over time. In 2021, there were 111.12 million cases 3.02 132,030 cancer. Between 2000 was 14.66% increase 38.68% 94.12% prevalence. While prevalence rate for increased (APC: 0.59%, [CI] 0.52 0.67%) these years, it decreased ALD -0.71%, CI -0.75 -0.67%) AUD -0.90%, -0.94 -0.86%). There significant variation by region, socioeconomic development level, sex. During last years (2019-2021), prevalence, incidence, death greater extent females. Given high cancer, urgent measures are needed prevent them at both national levels.

Language: Английский

Citations

5
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States DOI Open Access
Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 5, 2025

ABSTRACT Objective Primary liver cancer (PLC) is projected to be the third leading cause of mortality in United States 2040. We examine burden PLC States, stratified by sex, state and aetiological risk factors. Methods Data on prevalence, incidence, death disability–adjusted life years (DALYs) were extracted from Global Burden Disease Study 2021. Changes these parameters calculated using Joinpoint regression model. Results There 47,970 cases, 31,450 incident 24,770 deaths 576,920 DALYs States. The highest prevalence (16,980), incidence (12,040), (9840) (213,410) due chronic hepatitis C virus infection. From 2000 2021, incidences increased 141%, 136%. Age–standardised rates (ASIRs) (ASDRs) per 100,000 population for increased, primarily driven alcohol–related disease (ALD) (ASIR: annual percent change [APC]: +2.40%; ASDR: APC: +2.22%) metabolic dysfunction–associated steatotic (MASLD) +2.32%; +2.04%). Conclusion has risen past two decades, mainly ALD followed MASLD. These findings offer policymakers an accurate assessment emphasise need targeted factor mitigation, especially regarding alcohol related policy.

Language: Английский

Citations

4
Clinical Trial to Assess the Safety and Tolerability of Anti‐IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol‐Associated Liver Disease DOI Open Access
Luis Antonio Díaz,

Sheldon Morris,

Shravan Dave

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

ABSTRACT Background There are no FDA‐approved therapies for alcohol‐associated liver disease (ALD). Preclinical studies indicate that blocking IL‐23/IL‐17 signalling may reverse injury. Guselkumab, an IL‐23‐specific antibody approved psoriasis, be beneficial ALD. Aims We aimed to assess the safety and tolerability of guselkumab in patients with Methods This phase‐1 dose‐escalation study included ≥ 2 DSM‐5 criteria alcohol use disorder, significant steatosis (MRI‐PDFF 8%) MRE < 3.63 kPa (to exclude advanced disease). Guselkumab was given subcutaneously on Days 1 29 30, 70 or 100 mg dose cohorts. Primary endpoints were adverse events (AEs) dose‐limiting toxicity. Results enrolled 13 (three 30 mg, three seven mg). Eleven completed two early discontinued group. Of them, 77% men, median age 53 [IQR 49–61] years. The MRI‐PDFF 18.4% 8.4%–34.0%] 2.5 [2.2–2.6] kPa, respectively. most frequent AEs hyperuricemia (13%, mild only) elevated lipase (11%, moderate). serious variations enzymes. a suppression peripheral interleukin (IL)‐17, IL‐23, IL‐1b TNF‐α groups, decrease consumption over time (AUDIT‐C: 6 [3–7] vs. 5 [1–6], p = 0.023). Conclusions is safe doses up reduce inflammation markers These findings support further phase evaluate efficacy ALD, particularly severe phenotypes.

Language: Английский

Citations

2
Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly DOI Creative Commons
Pojsakorn Danpanichkul, Kanokphong Suparan, Cheng Han Ng

et al.

JHEP Reports, Journal Year: 2024, Volume and Issue: 6(4), P. 101020 - 101020

Published: Jan. 26, 2024

Abstract

Background & Aims

Alcohol-associated liver diseases (ALDs) and alcohol use disorder (AUD) pose a global health risk. AUD is underrecognized in the elderly, burden of complications, including ALD, may increase with aging populations rising intake. However, there lack epidemiological evidence on ALD elderly.

Methods

Using Global Burden Disease Study 2019, we analyzed prevalence, mortality, disability-adjusted life years (DALYs), age-standardized rates (ASRs), temporal change from 2000 to 2019 overall population elderly (65–89 years). The findings were categorized by sex, region, nation, sociodemographic index.

Results

prevalence higher than those adolescents young adults, whereas levels lower adults. In 9.39 million cases (8.69% population) AUD, 3.23 (21.8% alcohol-associated cirrhosis, 68,468 (51.27% cancer among ASRs increased most regions; contrary, death DALYs decreased regions. Nevertheless, many areas.

Conclusions

Our highlighted comparable that population. Public strategies targeting are urgently needed.

Impact implications

disease (ALD) increasing. Advances healthcare education have resulted remarkable spike expectancy consequential aging. little known about epidemiology study indicates increasing population, necessitating early detection, intervention, tailored care unique needs complexities faced older individuals grappling these conditions.

Language: Английский

Citations

15